Florence Lai Tiong

539P Final real-world safety and effectiveness results of REALITY-01 study: Trastuzumab deruxtecan (T-DXd) in patients received ≥2 prior treatment lines for HER2+ metastatic or unresectable (m/u) breast cancer (BC)

J-Y Pierga, Bernard Asselain, Luís Teixeira, C. Lévy et autres

fr, re (code pays fourni par la source)

Trastuzumab deruxtecan in previously treated HER2 ‐positive metastatic or unresectable breast cancer: Real‐life data from the temporary use authorization program in France

Thierry Petit, Nawale Hajjaji, E Antoine, Marc‐Antoine Benderra et autres

fr (code pays fourni par la source)

190P French real-world safety and effectiveness of trastuzumab deruxtecan (T-DXd) in the treatment of patients (pts) with HER2+ metastatic or unresectable breast cancer (m/u BC): First results of REALITY-01 ambispective study

J-Y Pierga, Bernard Asselain, Luís Teixeira, C. Lévy et autres

fr, re (code pays fourni par la source)

Abstract P2-13-26: Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer (BC): First real-life data from the cohort temporary authorization for use (cATU) program in France

Thierry Petit, Nawale Hajjaji, Éric-Charles Antoine, Marc‐Antoine Benderra et autres

fr, re (code pays fourni par la source)

A Rare Case of Pelvic Primitive Neuroectodermal Tumor in a 37-Year-Old Patient

Florence Lai Tiong

fr (code pays fourni par la source)

A Rare Case of Pelvic Primitive Neuroectodermal Tumor in a 37-Year-Old Patient

Florence Lai Tiong

fr (code pays fourni par la source)

About the Rare Case of a Pelvic Primitive Neuro-ectodermal Tumor in a 37 Year Old Patient

Florence Lai Tiong